中文

Iovance falls 35% after lung cancer update highlights a small subgroup

By · AI-assisted, human-reviewed and edited · · Updated · 11 sources · Fact-checked · 5 min read

Why is Iovance stock down today?

Iovance called the results of its trial in previously treated non-squamous non-small-cell lung cancer, a major category of lung cancer, positive on Wednesday evening, without numbers, and the stock rose about 12% after hours; on Thursday it fell 35% once the data were out. Tumors shrank in about 1 in 4 patients, close to an earlier update, with most responses in a small subgroup identified after the fact. Iovance will test that subgroup in a new group of patients within the same trial, while keeping its broader 2027 filing plan.

Move
▼ 35.4%
Price
$14.81 → $9.56
Value lost
~$2.4B
After-hours gain Wednesday
▲ ~12%
Response rate, all
24.6% of 69
KRAS-mutant response rate
11.4% of 35

Prices: official close, Nasdaq, Oct 29, 2026 · Company data: 10-Q, Jun 30, 2026 · What these numbers mean

Nasdaq closing prices on Oct 28 and Oct 29, 2026. The intraday low was $9.35. Value lost is our estimate, using the 453.0 million shares Iovance reported outstanding on Jul 29, 2026.

Snapshot at the Oct 29, 2026 close

Enterprise value
$4.1B
Price/sales
13.4×
EV/sales
12.5×
P/E
n/m
Revenue growth
+35%
Net cash
$298M

Our calculation from the company's filings (latest: 10-Q for the quarter to Jun 30, 2026, filed Aug 6, 2026); not investment advice. Revenue, earnings and cash flow: 12 months to Jun 30, 2026. Price $9.56 (official close, Nasdaq). n/m = not meaningful (e.g. negative earnings).

What happened

Iovance called its lung cancer results positive before giving any numbers; when the numbers came out the next morning, the stock lost more than a third of its value.

  • At 7 p.m. ET on Wednesday, Oct 28, Iovance announced a Thursday webcast to “highlight positive results” from the registrational part of its lung cancer trial. The notice gave no data. The stock rose about 12% after hours, Investing.com reported.
  • At 7 a.m. ET on Thursday, the company released the data. The shares gave up the overnight gain before the market opened and closed down 35.4% at $9.56, after a low of $9.35 (Nasdaq).
  • Using the 453.0 million common shares Iovance reported outstanding on July 29, we estimate the drop erased about $2.4 billion from Wednesday’s market value of about $6.7 billion.
  • The SPDR S&P Biotech ETF (XBI) closed up 0.2%, according to Stock Analysis. The Nasdaq Composite fell 1.4% and the S&P 500 fell 0.3%, AP reported.

What Iovance tested

The treatment is lifileucel, the same one-time cell therapy Iovance already sells as Amtagvi for advanced melanoma.

  • Doctors remove part of a patient’s tumor. Iovance grows the immune cells found inside it, called tumor-infiltrating lymphocytes (TIL), into billions of cells and infuses them back into the patient.
  • The trial, IOV-LUN-202, treats people with advanced non-squamous lung cancer whose disease kept growing after chemotherapy and immunotherapy. Its main measure is the response rate: the share of patients whose cancer disappears or whose selected tumor measurements shrink by at least 30%, under standard scan rules.
  • Iovance cites a separate study in which docetaxel chemotherapy produced a 12.8% response rate in similar patients. That was not a head-to-head comparison.

Iovance’s Oct 29 release reports results through an Oct 14 data cutoff for 69 patients who received at least 10 billion viable cells. It split them by KRAS and HER2, two genes doctors test for changes in the tumor:

Patients Number Response rate
All patients in the analysis 69 24.6% (17)
No KRAS mutation 30 43.3% (13)
KRAS mutation 35 11.4% (4)
No KRAS or HER2 mutation, current or former smokers 22 59.1% (13)

Four patients’ KRAS status was not assessed. Iovance reported 15 confirmed responses and two awaiting confirmation; confirmed responses alone are 21.7% of the 69 patients (our calculation). Independent review of the scans, the basis of the trial’s main measure, is still under way. The release did not give the length of responses or survival figures; it said durability and safety were consistent with earlier reports.

Why the market reacted this way

The shares reversed their overnight gain after the data came out. Investing.com’s trial-data report linked the early decline to the update, highlighting the similar overall response rate and the concentration of responses in a small subgroup. A separate Investing.com report cited profit-taking and tempered expectations. Both came before most of the day’s fall. The facts behind that reading:

  • At 24.6%, the overall response rate was in line with the 25.6% in 39 patients at an earlier data cutoff, in October 2025.
  • Patients in the best subgroup were under a third of the trial but accounted for 13 of the 17 responses. Among patients whose tumors had a KRAS mutation, about 1 in 9 responded.
  • Iovance identified that subgroup by looking back at the data, and only 22 patients are in it. Its release cautions that results from retrospective subgroup analyses may not be confirmed.
  • Iovance is adding POSITILITY, a new group of patients within IOV-LUN-202 that enrolls only the best-responding type of patient. It intends this group to support a potential path to approval, subject to FDA feedback. Separately, it still plans to file for approval in non-squamous lung cancer in 2027, based on the roughly 80 patients in the current trial groups, and says discussions with the FDA are ongoing.

Does this change Iovance’s future?

What did NOT change

  • Amtagvi remains available under FDA accelerated approval, which requires further evidence to confirm clinical benefit, for advanced melanoma after specified prior treatments. Iovance’s Sept 29 announcement raised its 2026 total revenue guidance for Amtagvi and Proleukin to $410–420 million; the company said that implies nearly 60% annual growth.
  • Iovance said in October that its cash and investments, including restricted cash, about $304 million at June 30, should last into the second half of 2028.
  • The 2027 filing plan for the broader lung cancer population is still in place.

What DID change

  • Iovance is adding studies that select patients using tumor gene tests and smoking history, while keeping its broader lung cancer filing plan. It estimates that the patients targeted by POSITILITY (after earlier treatment) and OPTILISM (a first-treatment study it plans to start in 2027) make up about 45% of newly diagnosed US non-squamous metastatic lung cancers.
  • The subgroup result still has to be confirmed in new patients. Iovance says FDA discussions are ongoing, and POSITILITY’s potential path to approval is subject to FDA feedback.
  • Iovance is still losing money. Its second-quarter filing reports a $126 million loss for the first half of 2026 and about $90 million of unused capacity to sell new shares through its at-the-market program.

Our read

Thursday’s overall numbers were in line with Iovance’s last update; what changed is how the benefit splits between patients, and that the strongest result comes from a small, after-the-fact subgroup. The key uncertainties are whether Iovance makes its planned 2027 filing, how the FDA assesses it, and whether POSITILITY confirms the subgroup finding.

What to watch next

Next few days
Analysts' responses to the updated data.
Thu Nov 5, 8:30 a.m. ET
Third-quarter results: total revenue (Amtagvi plus Proleukin) against the raised 2026 guidance of $410–420 million, and cash.
November 2026
Enrollment starts in POSITILITY, a new group of patients within the same trial, limited to the subgroup that responded best.
2027
The planned filing for FDA approval in non-squamous lung cancer, based on the current trial groups, and further updates on that broader program.

Quick questions

Did the lung cancer trial fail?

Iovance did not report a failure. The overall response rate of 24.6% was in line with its earlier update, and the company still plans a 2027 filing for FDA approval. But most responses came from a subgroup identified after the fact, which Iovance will now test in a new group of patients within the existing trial.

Does this affect Amtagvi in melanoma?

Amtagvi remains available under FDA accelerated approval for advanced melanoma after specified prior treatments; Thursday's update concerns its experimental use in lung cancer. In September, Iovance raised its 2026 total revenue guidance to $410–420 million.

Does Iovance have enough cash?

Iovance said its cash and investments, including restricted cash, about $304 million at June 30, should last into the second half of 2028. It is still losing money and has a program to sell new shares on the market.

About Iovance: Website (external site)Investor relations (external site)SEC filings (external site)Wikipedia (external site)

Quoting this? You may quote short excerpts under our reuse policy. Please credit WhyMyStockMoved.com and link to this page.